dMMR Recurrent or Advanced
Endometrial Cancer

JEMPERLI—a PD-1 checkpoint inhibitor that may light the way for your patients whose disease has progressed on or after treatment with a platinum-containing regimen.1

JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.


This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Icon: JEMPERLI (dostarlimab-gxly) Mechanism of Action

Learn how JEMPERLI
activates T cells.

Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety profile
and tolerability of JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.